<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909879</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-ARDS-201</org_study_id>
    <nct_id>NCT04909879</nct_id>
  </id_info>
  <brief_title>Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome</brief_title>
  <official_title>Treatment of Non-COVID-19 Acute Respiratory Distress Syndrome: A Phase 2 Study of the Efficacy and Safety of Intravenous Allogeneic Adipose-Derived Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 randomized study to assess the safety and efficacy of COVI-MSC in the&#xD;
      setting of current standard of care treatments for subjects hospitalized subjects with acute&#xD;
      respiratory distress syndrome not related to COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy&#xD;
      of COVI-MSC in the setting of current standard of care treatments for subjects hospitalized&#xD;
      subjects with acute respiratory distress syndrome not related to COVID-19 infection.&#xD;
&#xD;
      Subjects will be randomized 2:1 to receive COVI-MSC or placebo. COVI-MSC or placebo will be&#xD;
      administered intravenously on Day 0, Day 2, and Day 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Replaced by a different protocol.&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality rate at Day 28</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>All-cause mortality rate at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality rate at Days 60 and 90</measure>
    <time_frame>Baseline to Day 60 and Day 90</time_frame>
    <description>All-cause mortality rate at Days 60 and 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days through Day 28</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Number of ventilator-free days through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU days through Day 28</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Number of ICU days through Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status at Day 28</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Clinical status as assessed using the Ordinal Scale for Clinical Improvement (0-8 scale, where lower score means better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygenation</measure>
    <time_frame>Baseline to Day 2, Day 4, Day 6, Day 14, Day 28</time_frame>
    <description>Change in oxygenation at Days 2, 4, 6, 14, and 28 as measured using PaO2:FiO2 ratio.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Ards</condition>
  <arm_group>
    <arm_group_label>COVI-MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of ≈ 30 million cells) on Day 0, Day 2, and Day 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVI-MSC</intervention_name>
    <description>COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells</description>
    <arm_group_label>COVI-MSC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Excipient solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Negative for SARS-CoV-2 infection as determined by an approved polymerase chain&#xD;
             reaction (PCR) or an approved antigen test of any specimen&#xD;
&#xD;
          -  Hospitalized with non-COVID-19-induced ARDS (any severity) with a PaO2/FiO2 (PF ratio)&#xD;
             ≤ 300&#xD;
&#xD;
          -  Requires oxygen supplementation at Screening&#xD;
&#xD;
          -  Willing to follow contraception guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current standard of care treatments for ARDS appear to be working and the subject is&#xD;
             clinically improving&#xD;
&#xD;
          -  A previous stem cell infusion unrelated to this trial&#xD;
&#xD;
          -  Pregnant or breast feeding or planning for either during the study&#xD;
&#xD;
          -  Suspected uncontrolled active bacterial, fungal, viral, or other infection&#xD;
&#xD;
          -  History of a splenectomy, lung transplant or lung lobectomy&#xD;
&#xD;
          -  Concurrent participation in another clinical trial involving therapeutic interventions&#xD;
             (observational study participation is acceptable)&#xD;
&#xD;
          -  Expected survival or time to withdrawal of life-sustaining treatments expected to be &lt;&#xD;
             7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics, Inc.</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

